Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes

This publication has 46 references indexed in Scilit:

• Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients
  Nephrology Dialysis Transplantation, 2008
• Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone
  Clinical Trials, 2008
• Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease
  Journal of the American Society of Nephrology, 2008
• Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
  New England Journal of Medicine, 2006
• Dyslipidemia, inflammation and dialysis outcomes: what we know now
  Current Opinion in Nephrology and Hypertension, 2006
• Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus
  Kidney International, 2005
• Effect of Rosiglitazone on Common Carotid Intima-Media Thickness Progression in Coronary Artery Disease Patients Without Diabetes Mellitus
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
• Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
  Clinical Therapeutics, 2000
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
  Diabetes Care, 2000
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
  The Lancet, 1998